About: Pirfenidone: A novel hypothetical treatment for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pirfenidone: A novel hypothetical treatment for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pirfenidone: A novel hypothetical treatment for COVID-19
Creator	Seifirad, Soroush
Source	Elsevier; Medline; PMC
abstract	Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects. Pirfenidone is approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF) for patients with mild to moderate disease. Pirfenidone could inhibit apoptosis, downregulate ACE receptors expression, decrease inflammation by several mechanisms and ameliorate oxidative stress and hence protect pneumocytes and other cells from COVID-19 invasion and cytokine storm simultaneously. Based on the pirfenidone mechanism of action and the known pathophysiology of COVID-19, I believe that pirfenidone has the potential for the treatment of COVID-19 patients.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.110005
bibo:pmid	32575019
has license	no-cc
sha1sum (hex)	b4e31f8443cab9925288ba43829b609ca11c3f49
schema:url	https://doi.org/10.1016/j.mehy.2020.110005
resource representing a document's title	Pirfenidone: A novel hypothetical treatment for COVID-19
has PubMed Central identifier	PMC7297676
has PubMed identifier	32575019
schema:publication	Med Hypotheses
resource representing a document's body	covid:b4e31f8443cab9925288ba43829b609ca11c3f49#body_text
is schema:about of	named entity 'Pirfenidone' named entity 'COVID-19' named entity 'ARDS' named entity 'COVID-19' named entity 'PROOFS' named entity 'COVID-19' named entity 'morbidity' named entity 'Pirfenidone' named entity 'comorbidities' named entity 'upregulation' named entity 'ROS' named entity 'anti-inflammatory' named entity 'lung biopsy' named entity 'virus' named entity 'collagen fibril' named entity 'virus' named entity 'COVID' named entity 'paraquat' named entity 'pirfenidone' named entity 'NADH-quinone oxidoreductase' named entity 'pirfenidone' named entity 'receptor expression' named entity 'organ damage' named entity 'methyl' named entity 'risk factors' named entity 'azithromycin' named entity 'fibronectin' named entity 'paraquat poisoning' named entity 'azithromycin' named entity 'COVID' named entity 'COVID' named entity 'tissue injury' named entity 'LPS' named entity 'pirfenidone' named entity 'lipopolysaccharide' named entity 'ARDS' named entity 'Anti-apoptotic' named entity 'mechanism of action' named entity 'collagen' named entity 'COVID-19' named entity 'lipid peroxidation' named entity 'TGF' named entity 'COVID' named entity 'oxidative stress' named entity 'inflammation' named entity 'collagen' named entity 'LXR-α' named entity 'vascular congestion' named entity 'clinical trials' named entity 'morbidity' named entity 'pirfenidone' named entity 'pirfenidone' named entity 'pirfenidone' named entity 'paraquat poisoning' named entity 'June 2020' named entity 'angiotensin II' named entity 'double-blind' named entity 'IPF' named entity 'Pirfenidone' named entity 'animal models' named entity 'fibril' named entity 'mitochondrial DNA' named entity 'fibrosis' named entity 'WBC' named entity 'immune reaction' named entity 'growth factors' named entity 'SARS' named entity 'IPF' named entity 'IPF' named entity 'ARDS' named entity 'pulmonary toxicity' named entity 'microscope' named entity 'connective tissue growth factor' named entity 'AT1R' named entity 'antifibrotic' named entity 'type 1' named entity 'pirfenidone' named entity 'COVID' named entity 'fibrosis' named entity 'inhalation' named entity 'pirfenidone'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software